You are viewing the site in preview mode

Skip to main content

Table 1 Clinical details of the patients

From: Efficacy and safety of plasma hemodiafiltration (PHDF) in pediatric patients with multiple organ dysfunction syndrome with shock and DIC: a preliminary study

Case 1 2 3 4 5 6 7 8 9
Age 3 d 5 d 8 d 2 mo 10 mo 12 mo 5 mo 40 mo 36 mo
Sex F M M M F M F F M
Weight (kg) 2.1 2.1 2.5 2.6 5.3 5.8 7.2 12 13
Underlying disease AS CoA/C CoA/C TGA TA Hypo RV
ASD
VSD 		(−) (−) (−)
Cause of ICU admissions CS CS CS DS DS CS CS HSES HSES
Infection (−) (−) (−) (+) (+) (−) (−) (+) (+)
FFP administration (ml) 120 120 120 120 240 240 480 720 720
QB (ml/min) 12 12 10 12 30 25 20 40 40
QD (ml/h) 500 500 500 500 1000 1000 1500 2000 2000
Hemofilter UT300S UT300S UT300S UT300S UT300S UT300S UT300S UT700S UT700S
Duration of PHDF (h) 5 5 5.5 5 5 4 5 4.5 4
Duration of CHDF (h) 935 56 664 280 744 86 61 589 132
PELOD-2 score at day 0 22 14 23 16 14 20 21 20 17
PMR by PELOD-2 score 0.98 0.49 0.98 0.71 0.49 0.94 0.96 0.94 0.80
28-day outcome(the day of death) Survival Survival Survival Survival Survival Death (4) Death (3) Survival Survival
  1. AS arterial stenosis, CoA/C coarctation complex, TGA transposition of the great arteries, TA truncus arteriosus, RV right ventricle, ASD atrial septal defect, VSD ventricular septal defect, CS cardiogenic shock, DS distributive shock, HSES hemorrhagic shock and encephalopathy, PMR predicted mortality rate, QB blood flow rate, QD dialysate flow rate, PHDF plasma hemodiafiltration, CHDF continuous hemodiafiltration, PELOD-2 Pediatric Logistic Organ Dysfunction 2
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us

\